Eledon Pharmaceuticals (ELDN) Net Income towards Common Stockholders (2013 - 2026)
Eledon Pharmaceuticals posted quarterly Net Income towards Common Stockholders of -$36.9 million for Q1 2026, down 515.58% year-on-year from $8.9 million in Q1 2025, and down 275.51% on a QoQ basis from -$9.8 million in Q4 2025.
Eledon Pharmaceuticals (ELDN) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$36.9 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 515.58% year-over-year to -$36.9 million; the trailing twelve-month figure through Mar 2026 stood at -$73.3 million (down 85.48% YoY), and the FY2025 full-year result was -$42.3 million, down 32.31% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$36.9 million, down from -$9.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $21.2 million in Q4 2024 and bottomed at -$58.4 million in Q4 2022.
- The 5-year median for Net Income towards Common Stockholders is -$10.5 million (2022), against an average of -$14.4 million.
- The widest annual swing landed in 2024, when Net Income towards Common Stockholders surged 159.35%; it then sank 515.58% in 2026.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$58.4 million in 2022, then soared by 114.03% to $8.2 million in 2023, then soared by 159.35% to $21.2 million in 2024, then slumped by 146.31% to -$9.8 million in 2025, then plunged by 275.51% to -$36.9 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$36.9 million (Q1 2026), -$9.8 million (Q4 2025), and -$16.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Eledon Pharmaceuticals | 419.90 Mn | 203.87 Mn | - | -36.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.94 Mn |
| Dec 31, 2025 | -9.84 Mn |
| Sep 30, 2025 | -16.13 Mn |
| Jun 30, 2025 | -10.36 Mn |
| Mar 31, 2025 | -6.00 Mn |
| Dec 31, 2024 | 21.24 Mn |
| Sep 30, 2024 | -15.70 Mn |
| Jun 30, 2024 | -39.03 Mn |
| Mar 31, 2024 | -19.50 Mn |
| Dec 31, 2023 | 8.19 Mn |
| Sep 30, 2023 | -11.20 Mn |
| Jun 30, 2023 | -10.35 Mn |
| Mar 31, 2023 | -11.11 Mn |
| Dec 31, 2022 | -58.38 Mn |
| Sep 30, 2022 | -10.47 Mn |
| Jun 30, 2022 | -9.25 Mn |
| Mar 31, 2022 | -9.86 Mn |
| Dec 31, 2021 | 28.25 Mn |
| Sep 30, 2021 | -9.82 Mn |
| Jun 30, 2021 | -7.38 Mn |
| Mar 31, 2021 | -8.50 Mn |
| Dec 31, 2020 | -6.50 Mn |
| Sep 30, 2020 | -6.14 Mn |
| Jun 30, 2020 | -2.59 Mn |
| Mar 31, 2020 | -8.18 Mn |
| Dec 31, 2019 | -4.17 Mn |
| Sep 30, 2019 | -2.92 Mn |
| Jun 30, 2019 | -4.09 Mn |
| Mar 31, 2019 | -4.88 Mn |
| Dec 31, 2018 | -4.58 Mn |
| Sep 30, 2018 | -3.50 Mn |
| Jun 30, 2018 | -3.19 Mn |
| Mar 31, 2018 | -2.80 Mn |
| Dec 31, 2017 | -2.11 Mn |
| Sep 30, 2017 | -2.97 Mn |
| Jun 30, 2017 | -6.67 Mn |
| Mar 31, 2017 | -1.36 Mn |
| Dec 31, 2016 | -3.74 Mn |
| Sep 30, 2016 | -1.58 Mn |
| Jun 30, 2016 | -883,000.00 |
| Mar 31, 2016 | -11.43 Mn |
| Dec 31, 2015 | -11.02 Mn |
| Sep 30, 2015 | -11.85 Mn |
| Jun 30, 2015 | -8.96 Mn |
| Mar 31, 2015 | -13.26 Mn |
| Dec 31, 2014 | -6.21 Mn |
| Sep 30, 2014 | -6.39 Mn |
| Jun 30, 2014 | -5.85 Mn |
| Mar 31, 2014 | -4.85 Mn |
| Dec 31, 2013 | -5.54 Mn |
| Sep 30, 2013 | -3.37 Mn |